Jenny Leeds is an investor for Counterpoint Global. She joined Morgan Stanley in 2019 and has eight years of investment experience. Prior to joining the firm, she was an associate and Equity Research Analyst at Bank of America Merrill Lynch (BAML) focused on biotechnology. Jenny received a Ph.D. in cancer biology and immunology from Memorial Sloan Kettering Cancer Center and a B.S. in biochemistry from Tufts University.